Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 7/20 | 0.62 |
| ▸ | SERPINC1 | P01008 | 3/20 | 0.60 |
| ▸ | CXCL10 | P02778 | 1/20 | 0.47 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.47 |
| ▸ | CCL2 | P13500 | 1/20 | 0.47 |
| ▸ | CCL5 | P13501 | 1/20 | 0.47 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.47 |
| ▸ | FGF1 | P05230 | 4/20 | 0.47 |
| ▸ | BDNF | P23560 | 2/20 | 0.43 |
| ▸ | PTN | P21246 | 1/20 | 0.43 |
| ▸ | MDK | P21741 | 1/20 | 0.43 |
| ▸ | FGF2 | P09038 | 1/20 | 0.43 |
| ▸ | HPSE | Q9Y251 | 3/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16656905 | 0.94 | F10 (0.63) | F10SERPINC1CXCL10CXCL8CCL2 | |
| SCHEMBL16656904 | 0.91 | F10 (0.60) | F10SERPINC1CXCL10CXCL8CCL2 | |
| SCHEMBL16656848 | 0.91 | F10 (0.60) | F10SERPINC1CXCL10CXCL8CCL2 | |
| SCHEMBL14817756 | 0.89 | F10 (0.69) | F10SERPINC1CXCL10CXCL8CCL2 | |
| SCHEMBL19762911 | 0.87 | F10 (0.60) | F10SERPINC1CXCL10CXCL8CCL2 | |
| SCHEMBL18883211 | 0.86 | F10 (0.81) | F10SERPINC1CXCL10CXCL8CCL2 | |
| SCHEMBL15199336 | 0.86 | F10 (0.81) | F10SERPINC1CXCL10CXCL8CCL2 | |
| SCHEMBL10157440 | 0.86 | F10 (0.81) | F10SERPINC1CXCL10CXCL8CCL2 | |
| SCHEMBL14665995 | 0.86 | F10 (0.81) | F10SERPINC1CXCL10CXCL8CCL2 | |
| SCHEMBL14960713 | 0.86 | F10 (0.81) | F10SERPINC1CXCL10CXCL8CCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003623-B2 | Derived from heparin having a mean molecular weight of 1500-3000 Daltons and an anti-Xa/anti-IIa ratio greater than 30; venous, arterial, or deep vein thromboses; pulmonary embolism; unstable angina; myocardial infarction; and cardiac ischemia | AVENTIS PHARMA S.A. (FR) | 2011-08-23 | — | — | US | disclosed |
| US-20080182820-A1 | Mixtures of sulfated oligosaccharides | AVENTIS PHARMA S.A. (FR) | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182820-A1 | Mixtures of sulfated oligosaccharides | SERPINC1, HPSE, OSTC | F10 31/4885SERPINC1 1/4885CXCL10 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.